The US FDA has cleared a new “basal insulin dose optimizer” function for the Dexcom G7 15-day continuous glucose monitor (CGM), which is set to launch separately on December 1, 2025. The “Smart Basal” ...

Please provide your email address to receive an email when new articles are posted on . An expected longevity of 2 or 3 days is the standard for insulin infusion sets that are currently on the market, ...

After collecting a long-awaited FDA clearance for the latest generation of its wearable continuous glucose monitor last December, Dexcom has offered a peek into the momentum behind its G7 diabetes ...

Hybrid closed-loop systems are increasingly gaining recognition as a gold-standard option for diabetes management, and medtech makers are jumping at the opportunity to add their own artificial ...